tbuckley/cabot-search huggingface dataset:
CD19-Specific T Cells for Treatment of Pediatric Acute Lymphocytic Leukemia Using Sleeping Beauty Transposition.
Authors: Harjeet Singh, Pallavi R. Manuri, Simon Olivares, Navid Dara, Margaret J. Dawson, Helen Huls, Dean A. Lee, Perry B. Hackett, Donald B. Kohn, Partow Kebriaei, Elizabeth J. Shpall, Richard Champlin, Laurence Cooper
Journal: Blood (2007)
Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity
Authors: Pierre Bedossa, Joan Tordjman, Judith Aron-Wisnewsky, Christine Poitou, Jean-Michel Oppert, Adriana Torcivia, Jean-Luc Bouillot, Valerie Paradis, Vlad Ratziu, Karine Clément
Journal: Gut (2016)

<h3>Objective</h3> Non-alcoholic fatty liver disease (NAFLD) is a frequent complication of morbid obesity, but its severity varies greatly and thus there is a strong need to better define its natural history in these patients. <h3>Design</h3> Liver biopsies were systematically performed in 798 consecutive patients with severe obesity undergoing bariatric surgery. Histology was compared with clinical, biological, anthropometrical and body composition characteristics. <h3>Results</h3> Patients with presumably normal liver (n=179, 22%) were significantly younger at bariatric surgery than patients with NAFLD (37.0 vs 44.4 years, p&lt;0.0001). However, both groups showed quite similar obesity duration, since patients with presumably normal liver reported the onset of obesity at a significantly younger age than those with NAFLD (14.8 vs 20.0 year, p&lt;0.0001). The trunk/limb fat mass ratio increased according to liver disease severity (presumably normal liver: 1.00, steatosis: 1.21, non-alcoholic steatohepatitis (NASH): 1.34, p&lt;0.0001), although the total body fat mass decreased (presumably normal liver: 50%, steatosis: 49.1%, NASH: 47.4%, p&lt;0.0001). The volume of subcutaneous adipocytes increased according to severity of liver disease but only in female patients (presumably normal liver: 8543 picolitres, steatosis: 9156 picolitres, NASH: 9996 picolitres). <h3>Conclusions</h3> These results suggest that young adults are more prone to store fat in subcutaneous tissue and reach the threshold of bariatric surgery indication before their liver is damaged. A shift of fat storage from subcutaneous to visceral adipose tissue compartment is associated with liver damages. Liver might also be targeted by subcutaneous hypertrophic adipocytes in females since hypertrophic adipocytes are more exposed to lipolysis and to the production of inflammatory mediators.
Unrelated Donor Transplants for Older AML Patients Using a Low Dose TBI Containing Regimen Are As Efficacious As Related Donor Transplants, and Exhibit Favorable Outcomes for Intermediate Risk Disease.
Authors: Gregory A. Yanik, John M. Magenau, Shin Mineishi, Attaphol Pawarode, Keith Alangaden, Edward M. Peres, Steven Goldstein, John E. Levine, Sung Choi, Carrie L Kitko, Moshe Talpaz, Daniel Couriel
Journal: Blood (2012)
Natural Killer (NK) Cells Respond to CMV Reactivation After Allogeneic Transplantation with An Increase in NKG2C+CD57+ Self-KIR+ NK Cells with Potent IFNγ Production
Authors: Bree Foley, Michael R Verneris, Julie Curtsinger, Sandra Lopez-Verges, Lewis L. Lanier, Daniel J. Weisdorf, Sarah Cooley, Jeffrey S. Miller
Journal: Blood (2011)
PWE-043 The UK Multicentre Audit of Management and Outcome of Autoimmune Hepatitis (AIH). Prednisolone or Budesonide (or Neither) – and for How Long?
Authors: VM Gordon
Journal: Gut (2016)

<h3>Introduction</h3> Standard treatment of AIH is corticosteroid-based. However there is no consensus regarding optimal dose or duration of steroid therapy. Budesonide had similar short-term efficacy to Prednisolone in a large randomised trial; but data are lacking on its longer term efficacy. We conducted an audit on management of AIH in 28 UK centres of varying size and report outcomes in relation to type, dose and duration of steroid treatment in this cohort. <h3>Methods</h3> We aimed to collect all prevalent cases since 2000 and all incident cases since 2007 by searching electronic patient letters, histology databases and hospital coding. Validation was by 1999 IAIHG diagnostic criteria. Information, on diagnosis, severity, treatment and outcome was entered into a web-based system. <h3>Results</h3> 1267 patients (80% female age (mean (range) 55 years (8–86)) were followed up for 4 (0–14) years. Initial treatment was Prednisolone in 1091 patients, Methyl-Prednisolone/Hydrocortisone in 20 patients (pooled with Prednisolone as outcomes similar) and Budesonide in 61 patients. 984 patients also received a steroid sparing agent (962 Thiopurines). The remaining 95 patients did not receive steroids (12 received Thiopurine monotherapy). Of these 95, 10 required liver transplantation, 3 of these &gt;1 year after diagnosis. Compared to the 1172 patients receiving steroids, the 95 who did not were older (58 vs 50 years p &lt; 0.001) but had similar prevalence of cardio-respiratory comorbidity, cirrhosis and decompensation at presentation. They had a higher all-cause and liver-related death/transplant rate (p &lt; 0.001), which persisted in multivariate analysis, and also (all-cause only) when patients with decompensation at presentation (n = 282) were excluded. All-cause and liver-related death/transplant rate were also associated with shorter duration of steroid therapy (p = 0.001 and 0.008) and with its discontinuation after initial normalisation of transaminases (p = 0.007 and 0.016), but not associated with initial dose of Prednisolone. Of the 61 patients initially receiving Budesonide, treatment was changed to Prednisolone in 13 after 8 (0.2–29) months. Compared to those initially receiving Prednisolone, those receiving Budesonide had (a) similar age and gender distribution (b) lower peak serum ALT (c) surprisingly, a similar frequency of cirrhosis (26% vs 25%) at presentation (d) similar serum ALT values and percentages achieving normal values after 6 (64% vs 68%) and 12 months (78% vs 75%) treatment (e) similar all-cause and liver-related death/transplant rate. <h3>Conclusion</h3> In this Multicentre UK Audit (a) 7% of patients with AIH did not receive steroids and had higher mortality than those receiving steroids (b) 5% of patients received Budesonide (one quarter with cirrhosis) and had similar mortality to those receiving Prednisolone. <h3>Disclosure of Interest</h3> None Declared
Lenalidomide Differentially Modifies the Genomic Profile and miRNA Expression of Mesenchymal Stromal Cells From Patients with 5q- Syndrome,
Authors: Sandra Muntión, Carlos Santamaría, Beatriz Roson, Carlos Romo, Olga López-Villar, Soraya Carrancio, Fermin M. Sanchez-Guijo, María Diez-Campelo, Maria-Eugenia Sarasquete, Javier de las Rivas, Marcos González, Jesus F. San Miguel, Maria-Consuelo del Cañizo
Journal: Blood (2011)
Procoagulant Platelet-Derived Microparticles Are Lower in Calreticulin-Than in-JAK2-Mutated Essential Thrombocythemia
Authors: Agnes Charpentier, Nathalie Cambier, Anne Bauters, Nathalie Trillot, Matthieu Wemeau, Olivier Nibourel, Veronique Tintillier, Jean-Loup Demory, Claude Preudhomme, Brigitte Jude, Sophie Susen
Journal: Blood (2014)
AB0565 Diffuse Alveolar Hemorrhage, Diagnosis, Treatment and 3-Year Prognosis in A Group of 32 Cases of Tertiary Centre
Authors: P. Bradna, J. Manak, T. Soukup, J. Toms, M. Kodeda
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> Diffuse alveolar hemorrhage (DAH) is severe, life-threatening syndrome, affecting the patients with systemic vasculitis and other systemic connective tissue diseases. It can be often the first manifestation of systemic disease. Frequently DAH is the acute incident, which often leads to the rapidly emerging respiratory and/or renal failure with requirement of ventilatory support and with high mortality rate. <h3>Methods</h3> Diffuse alveolar hemorrhage was diagnosed on the basis of bronchoscopy and CT examination in patients with rapidly progressive respiratory insufficiency or newly emerged hemoptysis. Artificial ventilation was started in majority of cases.Therapeutically were used high doses of steroids i.v. (1000 mg 3–5 times in the iv infusion), Cyclophosphamide pulse, and plasmapheresis in some cases. <h3>Results</h3> The group of patients consisted of 32 cases; the average age of patients was 54 years (20–71) years. In half of patients was the episode of DAH the first manifestation of the disease. 16 patients were pro3 ANCA-positive, 7 patients MPO-ANCA positive, 6 patient had known systemic connective tissue disease 46.8% of patients survive 3 years from the acute episode of DAH, including two with repeated hemorrhage. 15 patients died during the acute phase of the disease, 3 more died during next 3 years, two of them on an opportunistic infection. Steroids were used for all patients, cyclophosphamide in 71, plasmapheresis in 56%, and i.v. immunoglobulins for 6.25 percent of patients. Patients who survive 3 years after the acute episode, had significantly lower necessity of artificial ventilation (40 vs. 93%) against the fatal cases, unfavorable prognostic sign was long term connective tissue disease. Residual lung impairment is present in 53% of the surviving patients; the signs of pulmonary arterial hypertension are present in 20% of the surviving group. <h3>Conclusions</h3> Diffuse alveolar hemorrhage is a sudden life-threatening event with a high mortality rate (46%) in the acute phase and during the first 3 years after the acute episode (20% of survivors). Up to half of patients the episode of DAH may be the first manifestation of the disease. Survival of patient depends on rapid diagnosis and the initiation of intensive immunosuppressive therapy. Respiratory failure is the major negative quoad vitam prognostic factor. Suspect the diffuse alveolar bleeding is necessary always in the case of a rapidly progressive respiratory failure. Acute bronchoscopy and x-ray examination give diagnosis of DAH, which further specify the acute examination of ANCA antibodies (71% of the report was ANCA antibodies positive. <h3>Disclosure of Interest</h3> None declared
Differentiating selves facilitates group outcomes
Authors: Sarah E Ainsworth, Roy F Baumeister, Kathleen D Vohs
Journal: Behavioral and Brain Sciences (2016)

Abstract The target article proposed that differentiation of selves is a crucial moderator of group outcomes, such that differentiation of selves contributes to beneficial outcomes of groups while limiting undesirable outcomes. In this response, we aim to complement the target article by refining and expanding several aspects of the theory. We address our conceptualization of optimal group functioning, clarify the term differentiation of selves, comment on the two-step nature of our model, offer theoretical connections and extensions, and discuss applications and opportunities for future research.
The Analysis of Chronic GVHD after Cord Blood Transplantation in Comparison with Bone Marrow Transplantation.
Authors: Sachiko Seo, Naoyuki Uchida, Kazuya Ishiwata, Masanori Tsuji, Hisashi Yamamoto, Shinsuke Takagi, Daisuke Kato, Naofumi Matsuno, Kazuhiro Masuoka, Wake Atsushi, Shuichi Taniguchi
Journal: Blood (2007)
AB1068 Specific Diet for Gout - Can General Practicioner Educate Their Patients?
Authors: M.S. Panchovska, N.G. Nikolov, L.R. Despotova-Toleva
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Gout is a chronic disease that occurs with joint crises. Almost 50% of patients with gout are treated by general practitioners (GPs). Nonpharmacological treatment - proper diet and lifestyle, are held parallel with medication throughout life (1). <h3>Objectives</h3> The aim of the study was to analyze the training of GPs on gout diet and the opportunities for educating patients with gout in general practice. <h3>Methods</h3> A direct anonymous questionnaire among 37 GPs was performed. Seven (7) close questions with possible answers “yes” or “no” were included. Collected data were processed by alternative analysis. <h3>Results and discussion</h3> Unfavorable relationship between alcohol (beer, spirits, wine) noted 37 of all 37 respondents (100%). Regarding the increased intake of coffee and the worsening of gout information had 19 of the 37 GPs (51.35%). Nine of 37 respondents (2.43%) believe that black tea has unfavorable effect on gout. Traditionally recommended milk and yoghurt in gout noted as useful 33 of 37 (85.19%) of GPs. About the relationship between low-fat yogurt and worsening the in serum levels of uric acid 7 of 37 respondents (18.92%) are informed. Eleven (11) of 37 GPs (29,73%) are aware on the positive effect of vit.C supplementation on the relative frequency of joint crisis, as well as 5 of 35 (13,51%) noted the beneficial effects of vitamin D supplementation in gout. Regularly updated recommendations and guidelines for patients with gout are very helpful in their everyday life (2). New data about this disease known since the time of Hippocrates, are accumulated in recent years especially on gout diet (3,4). <h3>Conclusions</h3> Good medical practice requires constant upgrading of knowledge. The survey data has shown need to extend education programs for GPs about gout, focusing on diet as an essential part of the treatment. <h3>References</h3> Hak AE, Choi HK. Lifestyle and gout. Curr Opin Rheumatol, 2008 (20):179–86 Sivera F, Andres M,Carrmona I. et al. Multinational evidence-based recommendations for the diagnosis and management of gout:integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis 2014, 73(2):328–35 Torralba KD,De Jesus E, Rachabattula S.The interplay between diet,urate transporters and the risk for gout and hyperuricemia:current and future directions.Int J Rheum Dis. 2012 Dec,15(6):499–506.doi:10.1111&lt;1756-185X.12010.Epub 2012 Oct 22 Andres M,Sivera F,Falzon I. et al.Dietary supplements for chronic gout.2014 Cochrane Database Syst Rev (10),SD010156 <h3>Disclosure of Interest</h3> None declared
A Randomized Controlled Trial of Patient Controlled Analgesia Versus Continuous Infusion of Morphine during Vaso-Occlusive Crisis in Sickle Cell Disease.
Authors: Eduard J. van Beers, Pythia T. Nieuwkerk, Charlotte F.J. van Tuijn, Philip W. Friederich, Jan H. Vranken, Bart J. Biemond
Journal: Blood (2005)
PTU-075 Liver and Spleen Stiffness Measurements Based on Acoustic Radiation Force Impulse Elastography for Noninvasive Assessment of Esophageal Varices in HCV-Related Advanced Fibrosis
Authors: MS Abdelbary, S Kamal, A Albuhairi, A Khairy, N Zayed, A Yosry
Journal: Gut (2016)

<h3>Introduction</h3> Acoustic radiation force impulse elastography (ARFI) and Transient elastography (TE) are noninvasive methods of measuring liver stiffness (LS) and spleen stiffness (SS). They were proposed as non-invasive predictors of portal hypertension in patients with HCV-related cirrhosis, a highly prevalent disease in Egypt. This is the first egyptian study aimed to validate the reliability of liver and spleen stiffness measured by ARFI and other non-invasive methods as non-invasive predictors for presence of esophageal varices (EV). <h3>Methods</h3> This cross-sectional study included 200 patients (mean age was 54.9±8 years) with HCV-related advanced fibrosis (METAVIR score ≥F3) diagnosed by FibroScan® (≥ 9.5 kilopascal) including Child Turcotte Pugh class A/B liver cirrhosis; 82/18%. Demographic, clinical, biochemical, endoscopic and ultrasonographic data were collected. LOK index and FIB-4 score were calculated. Liver and spleen stiffness were assessed by 10 ARFI measurements, both in the liver and in the spleen; median values were calculated, expressed in m/sec. The accuracy of these diagnostic methods in diagnosing EV was evaluated on the basis of area under receiver operating characteristic (AUROC) curves. <h3>Results</h3> Liver stiffness measurement by FibroScan® revealed F4 in 95.5% and esophageal varices were present in 90 patients (39 Grade I, 30 Grade II, 18 Grade III, 3 Grade IV). Spleen longitudinal diameter (cutoff value 14.85 cm), splenic vein diameter(cutoff value 7.9 mm); platelets to spleen diameter ratio (cutoff value 960), LOK index (cutoff value 0.62)and FIB-4 score (cutoff value 2.81) were the best parameters among all the ultrasonographic and biochemical parameters for prediction of esophageal varices; AUROC 0.79, 0.76, 0.76, 0.74 and 0.71, respectively. Using ARFI, SS had better diagnostic performance than LS with cutoff value of 3.25 m/sec and 2.61 m/sec; AUROC =0.76 and 0.70, respectively. Moreover, the calculation of simple prediction models including LS and/or SS improved the reliability of ARFI for the prediction of esophageal varices; (Spleen longitudinal diameter × Splenic vein diameter × SS) and (LS× SS / Platelets/Spleen diameter ratio) with AUROC = 0.85 and 0.83 respectively. <h3>Conclusion</h3> Liver stiffness and spleen stiffness represent a non-invasive reliable tool for the prediction of clinically significant portal hypertension as evident by the presence of esophageal varices in chronic liver disease patients. <h3>Disclosure of Interest</h3> M. Abdelbary: None Declared, S. Kamal, None Declared, A. Albuhairi: None Declared, A. Khairy Grant/research support from: ABBVIE, Speaker bureau with: Astra Zeneca, N. Zayed Grant/research support from: ABBVIE, A. Yosry Consultant for: Roche, Janssen, Gilead, MSD, Speaker bureau with: Roche, Janssen, Gilead, MSD
Intensified Chop (CHOP14) Plus Rituximab in the Treatment of Elderly Patients with Aggressive and High Risk Non Hodgkin’s Lymphoma (NHL).
Authors: Luigi Rigacci, Luca Nassi, Renato Alterini, Valentina Carrai, Franco Bernardi, Varesco Martini, Paolo Bernardeschi, Giovanni Longo, Alberto Bosi
Journal: Blood (2004)
Cancer of unknown primary site with pathological characteristic of the breast cancer
Authors: Keiko Goto, Jun Hashimoto, Yuko Tanabe, Makoto Kodaira, Harukaze Yamamaoto, Mayu Yunokawa, Kan Yonemori, Chikako Shimizu, Kenji Tamura, Yasuhiro Fujiwara
Journal: Annals of Oncology (2015)
The mTOR Inhibitor Temsirolimus (CCI-779) Induces Cell Cycle Arrest and Autophagy in Hodgkin Lymphoma (HL) Cell Lines and Enhances the Effect of the PI3-Kinase Inhibitor LY294002.
Authors: Georgios V. Georgakis, Victor Y. Yazbeck, Yang Li, Anas Younes
Journal: Blood (2006)
SP0069 JIA and Other Paediatric Rheumatic Diseases
Authors: N. Ruperto
Journal: Annals of the Rheumatic Diseases (2016)

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disorder in children and is also a major cause of acquired disability and quality of life impairment in childhood. Children with oligoarticular JIA are usually treated with NSADS and intraarticular steroid injections. For children with polyarticular course JIA, methotrexate (MTX) is the drug of first choice since it provides significant clinical benefits, with an acceptable toxicity profile. For children not responding to MTX, the introduction of the biologic agents has determined a substantial advantage for the therapy of JIA since for the first time we have now drugs able to selectively block key components of the inflammation cascade. Biologic agents can be globally divided into 2 categories: drugs able to block the tumor necrosis factor (TNF) (etanercept, infliximab, adalimumab and others) and drugs with different mechanism of action (eg abatacept, tocilizumab, anakinra, canakinumab ecc). In general biologic agents, also for their elevated cost, have to administered in children with severe arthritis non responsive to conventional therapies, primarily MTX. The real novelty in these last years, has been the availability of biologic agents to be specifically used for the treatment of systemic JIA where, along with arthritis, children have systemic manifestations such as fever, rash, serositis, lymphadenopathy etc. These new drugs are indeed able to block selectively molecules that has been shown to be pivotal in the inflammatory process such as IL6 (tocilizumab) and IL 1 (anakinra, canakinumab and others) Most of the biologic agents have been tested (or are currently under study) thanks to the involvement of the Pediatric Rheumatology International Trials Organisation (PRINTO at www.printo.it) and of the Paediatric Rheumatology Collaborative Study Group (PRCSG at www.prcsg.org). This review will present a practically orientated overview of the "state of the art" for the treatment of JIA and the other major paediatric rheumatic disases including an overview on safety aspects. <h3>Disclosure of Interest</h3> N. Ruperto Grant/research support from: The Gaslini Hospital, which is the public Hospital where I work as full time public employee, has received contributions from the following industries: Abbott, BMS, "Francesco Angelini", GlaxoSmithKline (GSK), Hoffman-La Roche, Italfarmaco, Janssen, Novartis, Pfizer, Sanofi Aventis, Schwarz Biosciences, Sobi, Xoma, Wyeth. This money has been reinvested for the research activities of the hospital in a fully independent manners besides any committment with third parties., Speakers bureau: The undersigned Dr Nicolino Ruperto received honoraria for consultancy or speaker9s bureau from the following pharmaceutical companies: Abbott, AbbVie, Amgen, Biogenidec, Astellas, Alter, AstraZeneca, Boehringer, BMS, CD-Pharma,Celgene, CrescendoBio, EMD Serono,Hoffman-La Roche, Italfarmaco, Janssen, MedImmune, Medac, Novartis, Novo Nordisk, Pfizer, Sanofi Aventis, Servier, Takeda, Vertex.
Comment on Ferrannini et al. CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis. Diabetes Care 2016;39:1108–1114
Authors: Jens Jordan, Ali El-Armouche, Markolf Hanefeld, Stefan R. Bornstein, Andreas L. Birkenfeld
Journal: Diabetes Care (2016)

In a recent issue of Diabetes Care , Ferrannini et al. (1) postulated a “thrifty substrate” hypothesis suggesting that the benefit in heart failure outcomes in patients treated with the sodium–glucose cotransporter 2 (SGLT2) inhibitor empagliflozin in the BI 10773 (Empagliflozin) Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial is at least in part due to a switch in myocardial substrate metabolism away from fat and glucose oxidation toward an “energy-efficient super fuel like ketone bodies” (2). According to the authors, ketones improve myocardial work efficiency and function specifically in the failing heart (1,2). Indeed, evidence suggests that in heart failure, ketone use by the heart …
Associations between abdominal and general obesity and diabetic kidney disease: a cross-sectional study and a prospective study
Authors: Jinbo Hu, Shumin Yang, Aipin Zhang, Ping Yang, Xueting Cao, Richa Goswami, Yue Wang, Ting Luo, Kun Liao, Qingfeng Cheng, Xiaoqiu Xiao, Qifu Li
Journal: The Lancet Diabetes & Endocrinology (2016)